Skip To Main Content
Jaffer Ajani on Muck Rack

Jaffer Ajani

As seen in: Nature, Gut Journal, MDPI, Medscape, Annals of Oncology, The Lancet, Md Anderson Cancer Center, Chinese Clinical Oncology, Future Medicine, OncLive and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jaffer

Contact Jaffer, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

RhoA Y42C drives cell plasticity and PD-1-mediated immune evasion of diffuse gastric cancer

|
By Kyung-Pil Ko, Sangmin Kim Verified, Jinho Jang, Yoojeong Seo, Gengyi Zou, Jie Zhang, Sohee Jun, Brittany Morrow, Jaffer Ajani, Ryan Park, Yuan-Hung Lo, Michael Curran, Jae-Il Park, Kim Hyunki
| Nature Verified
Abstract Diffuse gastric cancer (DGC) is an aggressive gastric cancer subtype with a poor prognosis. The RHOA Y42C mutation is recurrent in DGC, but its independent oncogenic role is unclear. Next-Generation Sequencing of 431 DGC cases revealed that most RHOA mutations occurred without CDH1 alterations. Using genetically engineered gastric organoids, we show that RhoaY42C, along with KrasG12D and Trp53 loss (RKP), induces DGC, independently of Cdh1 loss.
Open in Who Shared Issue with article?

Can recurrence-free survival replace overall survival for resectable esophageal cancer?

|
By Jane Rogers, Jaffer Ajani
| cco.amegroups.org
Have a website account?Log In orRegister for exclusive website content. Home / Vol 15, No 3 (June 30, 2026) / Can recurrence-free survival replace overall survival for resectable esophageal cancer? PDF 28 views Full Text 3 views Peer Review File 13 views COI Form 11 views Session Timed Out Your session has expired. Please sign in again.
Open in Who Shared View Duplicates (11) Issue with article?

Optimizing First-line Therapy in Metastatic Esophageal Squamous Cell Carcinoma

|
By Jaffer Ajani
| Medscape Verified
Unresectable or metastatic esophageal squamous cell carcinoma (ESCC) is a resistant cancer with a poor prognosis. In this ReCAP, first-line treatment strategies are reviewed by Dr Jaffer Ajani of MD Anderson Cancer Center, Houston. Because ESCC frequently expresses PD-L1, immunochemotherapy is improving outcomes for a percentage of patients. Three major trials demonstrated improved survival with the addition of immunotherapy to chemotherapy.
Open in Who Shared Issue with article?
See all 35 licensed articles (40 Total)